A New HOPE? Lessons from Heart Outcomes Prevention Evaluation-3

Travis M. Howard*, Aakash A. Bavishi, Neil J. Stone

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations


Lifestyle modification is the cornerstone of preventing atherosclerotic cardiovascular disease. When this is not sufficient in reducing risk, statin therapy is first line. Heart Outcomes Prevention Evaluation (HOPE-3) was a randomized controlled trial of rosuvastatin versus placebo, which demonstrated a significant net benefit in a lower-risk population without known atherosclerotic cardiovascular disease. There were many novel characteristics about this trial that should not be overlooked. It contained a diverse population and was the first trial to base inclusion solely on easily ascertainable metabolic risk factors. It had high adherence in the statin arm, likely due to several factors, including a run-in phase, close follow-up, and low intolerance of moderate-dose rosuvastatin. Attempting to simulate these could increase adherence among clinic populations. Although HOPE-3 did not demonstrate a significant decrease in cardiovascular events among women, meta-analysis including prior randomized controlled trials still demonstrates significant benefit, supporting prior guidelines for statin therapy in this group. Finally, HOPE-3 provides data that potentially support the legacy effect of statins. Understanding these key points provides additional insight into the benefits of statin therapy.

Original languageEnglish (US)
Pages (from-to)134-140
Number of pages7
JournalAmerican Journal of Medicine
Issue number2
StatePublished - Feb 2018


  • Adherence
  • HOPE-3
  • Legacy effect
  • Randomized controlled trial
  • Statin
  • Women

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'A New HOPE? Lessons from Heart Outcomes Prevention Evaluation-3'. Together they form a unique fingerprint.

Cite this